Home / Health / Teva planned for second generic Copaxone to enter market in 2018

Teva planned for second generic Copaxone to enter market in 2018

TEL AVIV (Reuters) – Israel-based Teva Pharmaceutical Industries stated on Tuesday it had anticipated and planned for a second generic competitor to its a number of sclerosis remedy Copaxone to enter the market in 2018.

Teva’s feedback got here after Novartis’s Sandoz division stated it has gained U.S. approval for a bigger dosage of its Glatopa drug for MS sufferers, its copy of Copaxone.

“We remain committed to providing Teva’s Copaxone 40 mg to patients and continuing to support our patients,” Teva stated in an emailed assertion to Reuters.

About viralpearladmin

Check Also

Popular push for Austrian smoking ban gathers pace

VIENNA (Reuters) – More than 200,000 Austrians have signed a petition calling for a ban …

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: